川宁生物
(301301)
| 流通市值：49.97亿 | | | 总市值：180.15亿 |
| 流通股本：6.19亿 | | | 总股本：22.32亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 735,139,582.72 | 876,180,496.06 | 664,172,368.15 | 734,213,300.93 |
| 交易性金融资产 | 150,226,236.4 | 170,170,475.99 | - | - |
| 应收票据及应收账款 | 959,307,146.23 | 1,039,875,000.23 | 1,148,278,179.14 | 1,033,108,420.33 |
| 应收账款 | 959,307,146.23 | 1,039,875,000.23 | 1,148,278,179.14 | 1,033,108,420.33 |
| 应收款项融资 | 475,817,150.07 | 587,969,959.36 | 862,634,114.86 | 751,491,043.35 |
| 预付款项 | 295,736,705.25 | 143,911,340.45 | 116,810,176.82 | 110,957,644.01 |
| 其他应收款合计 | 2,093,861.25 | 2,074,550.65 | 907,992.74 | 283,937.07 |
| 存货 | 1,686,441,707.53 | 1,402,282,919.79 | 1,322,095,281.76 | 1,500,308,074.01 |
| 其他流动资产 | 26,820,248.65 | 19,470,116.99 | 76,001,514.31 | 78,733,000.91 |
| 流动资产合计 | 4,331,582,638.1 | 4,241,934,859.52 | 4,190,899,627.78 | 4,209,095,420.61 |
| 非流动资产: | | | | |
| 长期股权投资 | 224,274,223.77 | 180,985,561.19 | 181,189,999.88 | 148,458,206.29 |
| 其他权益工具投资 | 25,224,217.92 | 25,224,217.92 | 25,224,217.92 | 25,224,217.92 |
| 其他非流动金融资产 | 58,516,782.11 | 46,516,782.11 | 46,516,782.11 | 28,516,782.11 |
| 固定资产 | 4,709,833,972.4 | 4,765,306,108.69 | 4,890,524,714.83 | 4,981,358,796.37 |
| 在建工程 | 279,601,516.35 | 329,143,281.44 | 309,547,501.21 | 277,214,374.89 |
| 使用权资产 | 459,226,065.95 | 463,776,680.53 | 468,327,295.11 | 472,245,747.95 |
| 无形资产 | 227,260,084.99 | 231,964,448.22 | 236,682,275.39 | 228,912,080.88 |
| 商誉 | 1,365,974 | 1,365,974 | 1,365,974 | 1,365,974 |
| 长期待摊费用 | - | 219,563.25 | 439,126.5 | 658,689.75 |
| 递延所得税资产 | 20,959,854.33 | 20,173,296.59 | 20,174,249.97 | 21,773,417.23 |
| 其他非流动资产 | 24,119,935.27 | 24,786,346.81 | 32,051,800.55 | 34,656,569.97 |
| 非流动资产合计 | 6,030,382,627.09 | 6,089,462,260.75 | 6,212,043,937.47 | 6,220,384,857.36 |
| 资产总计 | 10,361,965,265.19 | 10,331,397,120.27 | 10,402,943,565.25 | 10,429,480,277.97 |
| 流动负债: | | | | |
| 短期借款 | 625,133,319.36 | 748,438,411.11 | 760,482,252.22 | 560,353,307.78 |
| 交易性金融负债 | - | 217,381.95 | 901,170 | - |
| 应付票据及应付账款 | 790,428,439.94 | 662,230,587.4 | 695,586,302.01 | 710,489,881.38 |
| 其中：应付票据 | 153,000,000 | - | - | 0 |
| 应付账款 | 637,428,439.94 | 662,230,587.4 | 695,586,302.01 | 710,489,881.38 |
| 预收款项 | - | - | - | 0 |
| 合同负债 | 10,073,881.01 | 9,307,269.08 | 15,271,051.36 | 19,225,375.4 |
| 应付职工薪酬 | 28,637,826.9 | 29,106,752.21 | 27,592,915.43 | 29,008,471.96 |
| 应交税费 | 42,421,748.9 | 73,763,513.63 | 89,924,315.14 | 53,381,772.41 |
| 其他应付款合计 | 35,477,364.42 | 34,111,159.03 | 29,046,182.78 | 11,715,656.3 |
| 一年内到期的非流动负债 | 10,769,524.21 | 10,667,180.57 | 10,564,904.42 | 156,569,761.85 |
| 其他流动负债 | 202,099,937.23 | 201,615,375.19 | 1,743,318.7 | 203,629,074.71 |
| 流动负债合计 | 1,745,042,041.97 | 1,769,457,630.17 | 1,631,112,412.06 | 1,744,373,301.79 |
| 非流动负债: | | | | |
| 长期借款 | - | - | - | 0 |
| 租赁负债 | 449,777,513.21 | 447,149,044.23 | 448,062,665.43 | 469,731,985.1 |
| 预计负债 | 7,488,343.71 | 6,105,620.67 | 5,265,651.72 | 3,743,022.66 |
| 递延收益 | 100,824,996.5 | 102,874,561.12 | 100,055,815.74 | 103,799,153.17 |
| 非流动负债合计 | 558,090,853.42 | 556,129,226.02 | 553,384,132.89 | 577,274,160.93 |
| 负债合计 | 2,303,132,895.39 | 2,325,586,856.19 | 2,184,496,544.95 | 2,321,647,462.72 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 2,232,293,000 | 2,232,293,000 | 2,230,085,000 | 2,230,085,000 |
| 资本公积 | 3,305,756,176.09 | 3,305,756,176.09 | 3,298,859,644.84 | 3,298,263,225.6 |
| 其他综合收益 | 190,585.24 | 190,585.24 | 190,585.24 | 190,585.24 |
| 盈余公积 | 417,531,230.15 | 417,531,230.15 | 417,531,230.15 | 417,531,230.15 |
| 未分配利润 | 2,083,023,109.38 | 2,028,098,534.31 | 2,247,123,830.15 | 2,136,396,714.31 |
| 归属于母公司股东权益合计 | 8,038,794,100.86 | 7,983,869,525.79 | 8,193,790,290.38 | 8,082,466,755.3 |
| 少数股东权益 | 20,038,268.94 | 21,940,738.29 | 24,656,729.92 | 25,366,059.95 |
| 股东权益合计 | 8,058,832,369.8 | 8,005,810,264.08 | 8,218,447,020.3 | 8,107,832,815.25 |
| 负债和股东权益合计 | 10,361,965,265.19 | 10,331,397,120.27 | 10,402,943,565.25 | 10,429,480,277.97 |
| 公告日期 | 2026-10-23 | 2026-08-25 | 2026-04-23 | 2026-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |